Several recent population-based cohort studies have indicated that differences in ZMIZ1 expression due to gene mutations or epigenetic regulatory mechanism are significantly associated with the survival of cancer patients, including those with colon cancer (Arnau-Collell et al. 2020; Mathios et al. 2019; Song et al. 2017; Zhang et al. 2014). This evidence concerns the gene ZMIZ1 and malignant colon neoplasm.